Sanofi Heart Drug Multaq Linked To Liver Failure

Law360, New York (January 14, 2011, 3:40 PM EST) -- The U.S. Food and Drug Administration warned Friday that Multaq, Sanofi-Aventis SA's 18-month-old drug for heart problems, may be linked to liver damage in some patients, including two women whose livers failed.

Multaq, also known by the generic name dronedarone, has been connected with cases of “rare, but severe liver injury,” the FDA said in a warning to patients and doctors.

The drug was approved in the U.S. in July 2009 to treat abnormal heart rhythm and, through October 2010, about 492,000 prescriptions were dispensed, according...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.